Pharmacological and Nonpharmacological Factors That Contribute Blood Pressure Control
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Patient inclusion criteria were as follows:
- aged between 38 and 74 years,
- hypertension diagnosis history of at least 6 months
- use of at least one antihypertensive medication.
Exclusion Criteria:
-not willing to join the clinical trial
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
controlled hypertension
Controlled hypertension was defined as systolic blood pressure (SBP) ≤139 mmHg and/or diastolic blood pressure (DBP)≤89 mmHg for non-diabetic patients, and as SBP ≤139 mmHg and/or DBP ≤84 mmHg for diabetic patients, based on the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) guidelines.
observational study
|
|
uncontrolled hypertensive patients.
Individuals who had blood pressure levels above these values were defined as uncontrolled hypertensive patients.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
health related quality of life.
Time Frame: at the time of the beginning of the study
|
EQ-5D-3L turkish validation test
|
at the time of the beginning of the study
|
|
Age
Time Frame: at the time of the beginning of the study
|
years
|
at the time of the beginning of the study
|
|
Gender
Time Frame: at the time of the beginning of the study
|
Female/Male
|
at the time of the beginning of the study
|
|
BMI
Time Frame: at the time of the beginning of the study
|
(kg/m2)
|
at the time of the beginning of the study
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
complementary and alternative medicine use
Time Frame: at the time of the beginning of the study
|
subjective reports from patients (yes/no)
|
at the time of the beginning of the study
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Publications and helpful links
General Publications
- Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc. No abstract available.
- Özünal, Z. G., Tahirbegolli, I. A., Baykal, M., Belen, A. T. E. Ş., Tahirbegolli, B., KILIÇ, Y., ... & Üresin, A. Y. (2019). The drug adherence and lifestyle factors that contribute to blood pressure control among hypertensive patients.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 000001 (Other Grant/Funding Number: New York City Mayors Office Community Mental Health)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.